Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, as assessed by ambulatory blood pressure measurements.

Abstract

Olmesartan medoxomil is a new angiotensin II receptor blocker. In this randomized, double-blind, placebo-controlled study, the efficacy and safety of olmesartan medoxomil was assessed in 334 patients with moderate to severe essential hypertension. Patients were randomized to receive placebo; 5, 20, or 80 mg olmesartan medoxomil q.d.; or 2.5, 10, or 40 mg olmesartan medoxomil b.i.d. Ambulatory and cuff blood pressure were measured prior to and after 8 weeks of treatment. Treatment with olmesartan medoxomil resulted in a significant placebo-adjusted reduction of mean 24-hour ambulatory diastolic blood pressure of 9.6 mm Hg, 12.2 mm Hg, and 10.6 mm Hg in the 5-, 20-, and 80-mg q.d. groups, respectively. Corresponding reductions in mean ambulatory systolic blood pressure were 14.5 mm Hg, 16.5 mm Hg, and 15.4 mm Hg. Similar reductions of diastolic and systolic blood pressure were seen with b.i.d. dosing. The diastolic trough-to-peak ratios of the q.d. doses of olmesartan medoxomil ranged from 57%-70%, indicating 24-hour effectiveness. The safety profile of olmesartan medoxomil was similar to that of placebo. Olmesartan medoxomil appears to be a safe and effective once-a-day treatment for hypertension.

• Authors: Joel M Neutel, William J Elliott, Joseph L Izzo, Chao L Chen, Harvey N Masonson
• Journal: Journal of clinical hypertension (Greenwich, Conn.) (J Clin Hypertens (Greenwich)) 2002 Sep-Oct Vol. 4 Issue 5 Pg. 325-31 ISSN: 1524-6175 [Print] United States
• PMID: 12368570 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: Copyright 2002 Le Jacq Communications, Inc.

Chemical References

• Angiotensin Receptor Antagonists
• Antihypertensive Agents
• Imidazoles
• Tetrazoles
• Olmesartan Medoxomil

Topics

• Adult
• Angiotensin Receptor Antagonists
• Antihypertensive Agents (adverse effects, therapeutic use)
• Blood Pressure Monitoring, Ambulatory
• Dose-Response Relationship, Drug
• Double-Blind Method
• Female
• Humans
• Imidazoles (adverse effects, therapeutic use)
• Least-Squares Analysis
• Male
• Middle Aged
• Olmesartan Medoxomil
• Tetrazoles (adverse effects, therapeutic use)